Prospects for metabolic therapy in heart diseases

Abnormalities in cardiomyocyte energy metabolism underlie ischemic injury of the heart. However, traditional medicine does not usually set an objective to directly influence energy processes in the myocardium. Therefore, the prospects of developing drug therapy that involves metabolic agents able to successfully eliminate abnormalities in cell metabolism, ionic hemostasis, and membranes functions of the cardiomyocytes thereby preventing or reducing the development of irreversible processes in disease are quite promising.